Holger N. Lode

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 379 citations

Interleukin 2, Autoimmune Disease, Anti-gd2 Antibody Ch14.18/cho +7

Mutational dynamics between primary and relapse neuroblastomas

Alexander Schramm, Johannes Köster, Yassen Assenov et al. · Nature Genetics · 2015 · 314 citations

Tumor Heterogeneity, Mutational Dynamics, Pathology +4

Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of MicroRNA-34a Using Anti-Disialoganglioside GD2 Coated Nanoparticles

Amanda Tivnan, W. Shannon Orr, Vladimir Gubala et al. · PLoS ONE · 2012 · 232 citations · Full text

Bioactivation of Self-Immolative Dendritic Prodrugs by Catalytic Antibody 38C2

Marina Shamis, Holger N. Lode, Doron Shabat · Journal of the American Chemical Society · 2004 · 212 citations

Chemical Biology, Medicinal Chemistry, Biochemistry +14

NK cells engineered to express a GD₂‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin

Ruth Esser, Tina Müller, Dörthe Stefes et al. · Journal of Cellular and Molecular Medicine · 2011 · 183 citations · Full text

Cell Therapy, Immune Regulation, Immunology +19